Document is current
Any future updates will be listed below
-
Authors
Rai, Shivam
Grockowiak, Elodie
Hansen, Nils
Luque Paz, Damien
Stoll, Cedric B.
Hao-Shen, Hui
Mild-Schneider, Gabriele
Dirnhofer, Stefan
Farady, Christopher J. https://orcid.org/0000-0002-3607-9721
Méndez-Ferrer, Simón
Skoda, Radek C. https://orcid.org/0000-0002-3626-9496
-
Funding
Funding for this research was provided by:
Schweizerischer Nationalfonds zur Förderung der Wissenschaftlichen Forschung (31003A_166613, 310030_185297)
Krebsliga Schweiz (KFS-3655-02-2015, KFS-4462-02-2018)
- License Information
-
More Information
Article History
Received: 8 July 2021
Accepted: 24 August 2022
First Online: 13 September 2022
Competing interests
: R.C.S. has consulted for and received honoraria from Novartis and Celgene/BMS, he is a scientific advisor/SAB member and has equity in Ajax Therapeutics; N.H. owns stocks in the company Cantargia; C.J.F. is a full-time employee of Novartis Pharma AG. The inhibitor studies were carried out in the laboratory of R.C.S. with inhibitors provided by Novartis. The remaining authors declare no competing financial interests.
